clinical trial · NCT03277313
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Baxalta now part of Shire·phase3·completed·n = 44
Primary Immunodeficiency Diseases (PID)HYQVIA
brief summary
The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to \<16 years) participants with primary immunodeficiency disease (PIDD).
started
Sep 25, 2017
primary completion
Jul 20, 2022
completion
Jul 20, 2022
last updated
Oct 23, 2023
official title
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol